Solubility of lamotrigine in age-specific biorelevant media that simulated the fasted- and fed-conditions of the gastric and intestinal environments in pediatrics and adults: implications for traditional, re-formulated, modified, and new oral formulations

Shawahna, Ramzi; Saba’aneh, Hala; Daraghmeh, Amal; Qassarwi, Yara; Franco, Valentina; Declèves, Xavier

doi:10.1186/s12896-023-00809-2

Table 1 Age-specific dose number values in the 16 biorelevant media

From: Solubility of lamotrigine in age-specific biorelevant media that simulated the fasted- and fed-conditions of the gastric and intestinal environments in pediatrics and adults: implications for traditional, re-formulated, modified, and new oral formulations

Media	Dose number (D₀)
	Neonate (1 day to 6 months)	Age (years)
	Neonate (1 day to 6 months)	0.50	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	Adult (≥ 18)
FaSSGF	3.62	3.62	3.61	3.62	3.61	3.61	3.61	3.62	3.61	3.61	3.63	3.61	3.61	3.61	3.61	3.62	3.62	3.62	3.62	3.82
FeSSGF	1.49	1.49	1.49	1.50	1.49	1.49	1.49	1.50	1.49	1.49	1.50	1.49	1.49	1.49	1.49	1.50	1.50	1.50	1.50	1.58
FaSSIF.v2	16.57	16.57	16.55	16.57	16.55	16.56	16.57	16.57	16.56	16.56	16.63	16.53	16.54	16.54	16.53	16.60	16.59	16.58	16.58	17.50
FeSSIF.v2	4.52	4.52	4.51	4.52	4.51	4.52	4.52	4.52	4.52	4.52	4.54	4.51	4.51	4.51	4.51	4.53	4.52	4.52	4.52	4.77
Pn-FaSSGF	4.85	4.85	4.84	4.85	4.84	4.85	4.85	4.85	4.85	4.85	4.87	4.84	4.84	4.84	4.84	4.86	4.85	4.85	4.85	5.12
Pi-FaSSGF	4.73	4.73	4.73	4.73	4.73	4.73	4.73	4.73	4.73	4.73	4.75	4.72	4.73	4.73	4.72	4.74	4.74	4.74	4.74	5.00
Pnc-FeSSGF	2.09	2.09	2.09	2.09	2.09	2.09	2.09	2.09	2.09	2.09	2.10	2.09	2.09	2.09	2.09	2.10	2.10	2.09	2.09	2.21
Pns-FeSSGF	1.89	1.89	1.89	1.89	1.89	1.89	1.89	1.89	1.89	1.89	1.90	1.89	1.89	1.89	1.89	1.90	1.90	1.89	1.90	2.00
P-FaSSIF-50%	14.73	14.73	14.71	14.73	14.71	14.72	14.72	14.73	14.72	14.72	14.78	14.69	14.71	14.71	14.70	14.76	14.74	14.73	14.74	15.56
P-FaSSIF-150%	11.36	11.36	11.35	11.36	11.35	11.35	11.36	11.36	11.36	11.36	11.40	11.33	11.34	11.34	11.34	11.38	11.37	11.37	11.37	12.00
Pnb-FeSSIF	6.63	6.63	6.62	6.63	6.62	6.62	6.63	6.63	6.62	6.63	6.65	6.61	6.62	6.62	6.61	6.64	6.64	6.63	6.63	7.00
Pnc-FeSSIF	5.85	5.85	5.84	5.85	5.84	5.84	5.85	5.85	5.85	5.85	5.87	5.83	5.84	5.84	5.84	5.86	5.85	5.85	5.85	6.18
Pi-FeSSIF	4.19	4.19	4.18	4.19	4.18	4.18	4.18	4.19	4.18	4.18	4.20	4.18	4.18	4.18	4.18	4.19	4.19	4.19	4.19	4.42
FeSSGF (Phenylfree)	1.37	1.37	1.37	1.37	1.37	1.37	1.37	1.37	1.37	1.37	1.38	1.37	1.37	1.37	1.37	1.37	1.37	1.37	1.37	1.45
Pnc-FeSSGF (Phenylfree)	1.42	1.42	1.42	1.42	1.42	1.42	1.42	1.42	1.42	1.42	1.43	1.42	1.42	1.42	1.42	1.42	1.42	1.42	1.42	1.50
Pns-FeSSGF (Phenylfree)	1.41	1.41	1.41	1.41	1.41	1.41	1.41	1.41	1.41	1.41	1.42	1.41	1.41	1.41	1.41	1.41	1.41	1.41	1.41	1.49

Back to article page

ISSN: 1472-6750

Contact us

General enquiries: journalsubmissions@springernature.com

BMC Biotechnology

Contact us